JPRN-UMIN000047501
Completed
未知
A retrospective study to explore the efficacy and safety of FOLFOX therapy and FOLFOX with radiation in esophageal squamous cell carcinoma - A retrospective study to explore the efficacy and safety of FOLFOX therapy and FOLFOX with radiation in esophageal squamous cell carcinoma
ational Hospital Organization Nagoya Medical Center, Department of Medical Oncology0 sites143 target enrollmentApril 18, 2022
Conditionsesophageal squamous cell carcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- esophageal squamous cell carcinoma
- Sponsor
- ational Hospital Organization Nagoya Medical Center, Department of Medical Oncology
- Enrollment
- 143
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Duplicate cancers (simultaneous duplicate cancers and iatrogenic duplicate cancers with a disease\-free interval of 3 years or less). However, patients with overlapping cancers that are not prognostic factors are not excluded. Patients with cardiovascular complications that are not stabilized by pharmacological therapy alone.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A retrospective study to evaluate the efficacy and safety of carbon ion radiation therapy for primary lung cancer.primary lung cancerJPRN-UMIN000052389ational institutes for Quatum Science and Technology150
Completed
Not Applicable
A prospective study investigating the efficacy and safety of traction-band-assisted endoscopic closure for mucosal defect after colorectal endoscopic submucosal dissection: A multi-center trial (TBEC Trial)Colorectal neoplasmsJPRN-UMIN000047953Kitakyushu Municipal Medical Center34
Not yet recruiting
Phase 2
Chemoradiation and immunotherapy for unresectable skin squamous cell carcinomaskin cancersquamous cell carcinomaACTRN12618001573246Metro North Hospital and Health Service15
Active, not recruiting
Phase 1
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.Chronic spontaneous urticaria and the following skin disorders:1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermatitis, dyshidrotic eczema, asteatotic eczema, lichen simplex chronicus).2 - Prurigo (acute prurigo, subacute prurigo, chronic prurigo).3 - Cutaneous pruritus (systemic cutaneous pruritus, local cutaneous pruritus).MedDRA version: 19.0Level: HLTClassification code 10012435Term: Dermatitis and eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10037083Term: PrurigoSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10052568Term: Urticaria chronicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2016-001505-17-ESFAES FARMA, S.A.115
Active, not recruiting
Phase 1
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.EUCTR2016-001505-17-HUFAES FARMA, S.A.115